Fig. 6.
Fig. 6. Elastase release from neutrophils adherent to platelet monolayers in the presence of 10−7 mol/L PAF or 10−7 mol/L fMLP and either 50 or 500 nmol/L of the FLAP inhibitor MK886 or 100 nmol/L of the LTB4 receptor antagonist LY223982 (LTB4 ra). Data are expressed relative to values obtained from paired samples stimulated with fMLP alone (Con). Data are the mean ± SEM of six experiments using PAF or LY223982 and of three experiments for each intervention with MK886. Paired t-test showed that elastase release was significantly lower (**P < .01) than fMLP control for cells treated with PAF or cells treated with fMLP and LY223982 or 500 nmol/L MK886.

Elastase release from neutrophils adherent to platelet monolayers in the presence of 10−7 mol/L PAF or 10−7 mol/L fMLP and either 50 or 500 nmol/L of the FLAP inhibitor MK886 or 100 nmol/L of the LTB4 receptor antagonist LY223982 (LTB4 ra). Data are expressed relative to values obtained from paired samples stimulated with fMLP alone (Con). Data are the mean ± SEM of six experiments using PAF or LY223982 and of three experiments for each intervention with MK886. Paired t-test showed that elastase release was significantly lower (**P < .01) than fMLP control for cells treated with PAF or cells treated with fMLP and LY223982 or 500 nmol/L MK886.

Close Modal

or Create an Account

Close Modal
Close Modal